Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Expanded Trial of Vorasidenib in Japanese Patients with IDH1/2-Mutant Diffuse Glioma After Surgery Only
jRCT2061250027Active, not recruiting
- Sponsor
- Servier
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vorasidenib in diffuse midline glioma (DMG), Oligodendroglioma (OG) and astrocytoma, sponsored by Servier. Primary endpoint: Safety and tolerability (adverse events). Started Jun 2025; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
diffuse midline glioma (DMG)Oligodendroglioma (OG)astrocytoma
Beyond the preview
Go deeper on jRCT2061250027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250027.